Introducing new disease-modifying therapies (DMTs) for Alzheimer's disease demands a fundamental shift in diagnosis and care for most health systems around the world. Understanding the views of health professionals, potential patients, care partners and taxpayers is crucial for service planning and expectation management about these new therapies.

To investigate the public's and professionals’ perspectives regarding (1) acceptability of new DMTs for Alzheimer's disease; (2) perceptions of risk/benefits; (3) the public's willingness to pay (WTP).

Informed by the ‘theoretical framework of acceptability’, we conducted two online surveys with 1000 members of the general public and 77 health professionals in Ireland. Descriptive and multivariate regression analyses examined factors associated with DMT acceptance and WTP.

Healthcare professionals had a higher acceptance (65%) than the general public (48%). Professionals were more concerned about potential brain bleeds (70%) and efficacy (68%), while the public focused on accessibility and costs. Younger participants (18–24 years) displayed a higher WTP. Education and insurance affected WTP decisions.

This study exposes complex attitudes toward emerging DMTs for Alzheimer's disease, challenging conventional wisdom in multiple dimensions. A surprising 25% of the public expressed aversion to these new treatments, despite society's deep-rooted fear of dementia in older age. Healthcare professionals displayed nuanced concerns, prioritising clinical effectiveness and potential brain complications. Intriguingly, younger, better-educated and privately insured individuals exhibited a greater WTP, foregrounding critical questions about healthcare equity. These multifaceted findings serve as a guidepost for healthcare strategists, policymakers and ethicists as we edge closer to integrating DMTs into Alzheimer's disease care.

为阿尔茨海默病引入新的疾病缓解疗法 (DMT) 需要全世界大多数卫生系统的诊断和护理发生根本性转变。了解卫生专业人员、潜在患者、护理合作伙伴和纳税人的观点对于这些新疗法的服务规划和期望管理至关重要。

调查公众和专业人士对以下方面的看法：(1) 新 DMT 治疗阿尔茨海默病的可接受性； (2) 对风险/收益的看法； (3)公众的支付意愿(WTP)。

根据“可接受性理论框架”，我们对爱尔兰 1000 名公众和 77 名卫生专业人员进行了两项在线调查。描述性和多元回归分析检查了与 DMT 接受度和 WTP 相关的因素。

医疗保健专业人士的接受度 (65%) 高于公众 (48%)。专业人士更关心潜在的脑出血（70%）和疗效（68%），而公众则关注可及性和成本。年轻的参与者（18-24 岁）表现出更高的支付意愿。教育和保险影响支付意愿的决定。

这项研究揭示了人们对新兴 DMT 治疗阿尔茨海默病的复杂态度，从多个维度挑战了传统观点。令人惊讶的是，尽管社会对老年痴呆症的恐惧根深蒂固，但仍有 25% 的公众对这些新疗法表示厌恶。医疗保健专业人员表达了细致入微的担忧，优先考虑临床效果和潜在的脑部并发症。有趣的是，更年轻、受过更好教育和有私人保险的个人表现出更高的支付意愿，凸显了医疗保健公平性的关键问题。随着我们越来越接近将 DMT 纳入阿尔茨海默病护理，这些多方面的发现为医疗保健战略家、政策制定者和伦理学家提供了指导。